miércoles, 1 de abril de 2020

FDA closes review of Novartis data integrity scandal with no penalty

FDA closes review of Novartis data integrity scandal with no penalty

Daily Recap

STAT Plus: FDA closes review of Novartis data integrity scandal without punishing the drug maker

By ED SILVERMAN


RUBY WALLAU FOR STAT
After its review, the FDA decided it found significant and objectionable conditions, but these did not warrant further regulatory action.

No hay comentarios: